Corcym, a new independent medical device company entirely dedicated to supporting cardiac surgeons with the best solutions for structural heart disease, today announces the start of operations globally. Born from the acquisition of the heart valve business of LivaNova Plc (LivaNova) by Gyrus Capital (Gyrus), an investment fund operating in the health and sustainability sectors, Corcym – reports a note – enters the market with a broad portfolio of products for cardiac surgeons and their patients around the world. “We are delighted to announce the birth of Corcym globally,” comments Christian Mazzi, CEO of the company. “We enter the market today with a solid legacy and a consolidated product portfolio over more than 50 years. Our commitment is to become the reference point for cardiac surgeons and their patients. “The name of the new company – from the Latin Cor (heart) and Cym (Cymbalon, valve) – expresses its focus: supporting cardiac surgeons with the best solutions for structural heart diseases. Corcym is present in over 100 countries, with two main production sites in Saluggia, Italy, and Burnaby, Canada, and about 850 employees. “Our mission – underlines Mazzi – is to help cardiac surgeons to better care for patients, today and in the future. Our plan is to enhance our foundations in mechanical valves and fuel growth with our two product platforms Perceval® and Memo, as well as investing in research to develop new products and new collaborations. We have created Corcym as an agile, dedicated, customer-focused company and we have the support of Gyrus, a solid partner with an industry focus, ready to invest in our future ”. Clinical evidence will play a vital role in the future of Corcym’s heart valve technologies. The company will support a vibrant clinical program, in partnership with leading cardiac surgery professionals, to develop clinical trials and support their initiatives. Corcym also – concludes the company note – will continue and expand the training and training programs related to its devices.